Weight-Reducing Side Effects of the Antiepileptic Agents Topiramate and Zonisamide

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 209)

Abstract

Drug-induced weight alteration can be a serious side effect that applies to several therapeutic agents and must be referred to in the respective approved labeling texts. The side effect may become health threatening in case of significant weight change in either direction. Several antiepileptic drugs (AEDs) are associated with weight gain such as gabapentin, pregabalin, valproic acid, and vigabatrin and to some extent carbamazepine. Others are weight neutral such as lamotrigine, levetiracetam, and phenytoin or associated with slight weight loss as, e.g., felbamate. The focus of this chapter is on the two AEDs causing strong weight loss: topiramate and zonisamide. For both drugs, several molecular mechanisms of actions are published. We provide a review of these potential mechanisms, some of which are based on in vivo studies in animal models for obesity, and of clinical studies exploring these two drugs as single entities or in combinations with other agents.

Keywords

AED AMPA Animal models Anticonvulsant Antiepileptic Binge eating Bupropion Carbonic anhydrase Clinical studies Clozapine Drug combinations Drug induced Empatic® GABA Ion channels Mechanism of action Molecular mechanism Olanzapine Phentermine Potassium channel QNEXA® Side effect Sodium channel Topamax® Topiramate Weight gain Weight loss Weight modification Weight reducing Zonegran® Zonisamide 

References

  1. Angehagen M, Ben-Menachem E, Rönnbäck L, Hansson E (2003a) Topiramate protects against glutamate- and kainate-induced neurotoxicity in primary neuronal-astroglial cultures. Epilepsy Res 54(1):63–71PubMedCrossRefGoogle Scholar
  2. Angehagen M, Ben-Menachem E, Rönnbäck L, Hansson E (2003b) Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem Res 28(2):333–340PubMedCrossRefGoogle Scholar
  3. Angehagen M, Ben-Menachem E, Shank R, Rönnbäck L, Hansson E (2004) Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J Neurochem 88(2):320–325PubMedCrossRefGoogle Scholar
  4. Angehagen M, Rönnbäck L, Hansson E, Ben-Menachem E (2005) Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. J Neurochem 94(4):1124–1130PubMedCrossRefGoogle Scholar
  5. Antel J, Weber A, Sotriffer CA, Klebe G (2004) Multiple binding modes observed in X-ray structures of carbonic anhydrase-inhibitor complexes and other systems: consequences for structure-based drug design. In: Supuran CT, Scozzafava A, Conway J (eds) Carbonic anhydrase: its inhibitors and activators, CRC enzyme inhibitors series. CRC Press, Boca RatonGoogle Scholar
  6. Antel J, Gregory PC, Nordheim U (2006) CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders. J Med Chem 49(14):4008–4016PubMedCrossRefGoogle Scholar
  7. Arbaizar B, Gómez-Acebo I, Llorca J (2008) Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen Hosp Psychiatry 30(5):471–475PubMedCrossRefGoogle Scholar
  8. Aribi AM, Stringer JL (2002) Effects of antiepileptic drugs on extracellular pH regulation in the hippocampal CA1 region in vivo. Epilepsy Res 49:143–151PubMedCrossRefGoogle Scholar
  9. Astrup A, Toubro S (2004) Topiramate: a new potential pharmacological treatment for obesity. Obes Res 12(Suppl):167S–173SPubMedCrossRefGoogle Scholar
  10. Atli A, Dogra S (2005) Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med 6:225–234PubMedCrossRefGoogle Scholar
  11. Baptista T, ElFakih Y, Uzcátegui E, Sandia I, Tálamo E, Araujo de Baptista E, Beaulieu S (2008) Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22(6):477–495PubMedCrossRefGoogle Scholar
  12. Bays H (2010) Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease. Expert Rev Cardiovasc Ther 8(12):1777–1801PubMedCrossRefGoogle Scholar
  13. Ben-Menachem E (2007) Weight issues for people with epilepsy–a review. Epilepsia 48(Suppl 9):42–45PubMedCrossRefGoogle Scholar
  14. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U (2003) Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 11(4):556–562PubMedCrossRefGoogle Scholar
  15. Berghöfer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN (2008) Obesity prevalence from a European perspective: a systematic review. BMC Public Health 8:200PubMedCrossRefGoogle Scholar
  16. Bischofs S, Zelenka M, Sommer C (2004) Evaluation of topiramate as an anti-hyperalgesic and neuroprotective agent in the peripheral nervous system. J Peripher Nerv Syst 9:70–78PubMedCrossRefGoogle Scholar
  17. Biton V (2004) Zonisamide: newer antiepileptic agent with multiple mechanisms of action. Expert Rev Neurother 4:935–943PubMedCrossRefGoogle Scholar
  18. Biton V (2007) Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 30:230–240PubMedGoogle Scholar
  19. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH (2003) A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 11:722–733PubMedCrossRefGoogle Scholar
  20. Bussone G, Usai S, D'Amico D (2006) Topiramate in migraine prophylaxis: data from a pooled analysis and open-label extension study. Neurol Sci 27(Suppl 2):S159–S163PubMedCrossRefGoogle Scholar
  21. Campistol J, Campos J, Casas C, Herranz JL (2005) Topiramate in the prophylactic treatment of migraine in children. J Child Neurol 20:251–253PubMedGoogle Scholar
  22. Capuano A, Vollono C, Mei D, Pierguidi L, Ferraro D, Di Trapani G (2004) Antiepileptic drugs in migraine prophylaxis: state of the art. Clin Ter 155:79–87PubMedGoogle Scholar
  23. Casini A, Antel J, Abbate F, Scozzafava A, David S, Waldeck H, Schafer S, Supuran CT (2003) Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 13:841–845PubMedCrossRefGoogle Scholar
  24. Catterall WA (1999) Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv Neurol 79:441–456PubMedGoogle Scholar
  25. Chengappa KN, Gershon S, Levine J (2001) The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 3:215–232PubMedCrossRefGoogle Scholar
  26. Chong MS, Libretto SE (2003) The rationale and use of topiramate for treating neuropathic pain. Clin J Pain 19:59–68PubMedCrossRefGoogle Scholar
  27. Costa C, Tozzi A, Luchetti E, Siliquini S, Belcastro V, Tantucci M, Picconi B, Ientile R, Calabresi P, Pisani F (2010) Electrophysiological actions of zonisamide on striatal neurons: selective neuroprotection against complex I mitochondrial dysfunction. Exp Neurol 221:217–224PubMedCrossRefGoogle Scholar
  28. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281:235–242PubMedCrossRefGoogle Scholar
  29. De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT (2005) Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett 15:2315–2320PubMedCrossRefGoogle Scholar
  30. Dhellemmes P, Defoort S, Vinchon M (2008) Benign intracranial hypertension: the role of medical treatment. Neurochirurgie 54:717–720PubMedCrossRefGoogle Scholar
  31. Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771–784PubMedCrossRefGoogle Scholar
  32. Dodgson SJ, Shank RP, Maryanoff BE (2000) Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41(Suppl 1):S35–S39PubMedCrossRefGoogle Scholar
  33. Drake ME Jr, Greathouse NI, Renner JB, Armentbright AD (2004) Open-label zonisamide for refractory migraine. Clin Neuropharmacol 27:278–280PubMedCrossRefGoogle Scholar
  34. Dursun SM, Devarajan S (2000) Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 45(2):198PubMedGoogle Scholar
  35. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G (1999) A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology 52:1338–1344PubMedGoogle Scholar
  36. Fakhoury T, Murray L, Seger D, McLean M, Abou-Khalil B (2002) Topiramate overdose: clinical and laboratory features. Epilepsy Behav 3:185–189PubMedCrossRefGoogle Scholar
  37. Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among us adults, 1999–2008. JAMA 303(3):235–241PubMedCrossRefGoogle Scholar
  38. Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, Most MM, Fryburg DA (2010) Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring) 18:1646–1651CrossRefGoogle Scholar
  39. Francis J, Burnham WM (1992) [3H]Phenytoin identifies a novel anticonvulsant-binding domain on voltage-dependent sodium channels. Mol Pharmacol 42(6):1097–1103PubMedGoogle Scholar
  40. Fung EL, Nelson EA (2007) Oligohydrosis underestimated side effect with topiramate treatment. Indian J Pediatr 74(7):694PubMedCrossRefGoogle Scholar
  41. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR (2003) Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289:1820–1825PubMedCrossRefGoogle Scholar
  42. Gadde KM, Yonish GM, Foust MS, Wagner HR (2007) Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry 68:1226–9PubMedCrossRefGoogle Scholar
  43. Gaspari CN, Guerreiro CA (2010) Modification in body weight associated with antiepileptic drugs. Arq Neuropsiquiatr 68(2):277–281PubMedCrossRefGoogle Scholar
  44. Gebhardt S, Theisen FM, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC, Kühnau W, Schmidtke J, Remschmidt H, Hebebrand J (2010) Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther 35(2):207–211PubMedCrossRefGoogle Scholar
  45. Ghelardoni S, Bazinet RP, Rapoport SI, Bosetti F (2005) Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism. Psychopharmacology (Berl) 180:523–529CrossRefGoogle Scholar
  46. Gibbs JW III, Sombati S, DeLorenzo RJ, Coulter DA (2000) Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41(Suppl 1):S10–S16PubMedCrossRefGoogle Scholar
  47. Gryder DS, Rogawski MA (2003) Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 23(18):7069–7074PubMedGoogle Scholar
  48. Hahn MK, Remington G, Bois D, Cohn T (2010) Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. J Clin Psychopharmacol 30(6):706–710PubMedCrossRefGoogle Scholar
  49. Hasegawa H (2004) Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. Curr Med Res Opin 20:577–580PubMedCrossRefGoogle Scholar
  50. Hebebrand J, Volckmar AL, Knoll N, Hinney A (2010) Chipping away the ‘missing heritability’: GIANT steps forward in the molecular elucidation of obesity – but still lots to go. Obes Facts 3:294–303PubMedCrossRefGoogle Scholar
  51. Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM (2002) Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology 42:210–220PubMedCrossRefGoogle Scholar
  52. Hord AH, Denson DD, Chalfoun AG, Azevedo MI (2003) The effect of systemic zonisamide (Zonegran) on thermal hyperalgesia and mechanical allodynia in rats with an experimental mononeuropathy. Anesth Analg 96:1700–1706; table of contentsPubMedCrossRefGoogle Scholar
  53. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H (2007) Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32(2):289–297PubMedCrossRefGoogle Scholar
  54. TOP Institute Pharma; Project T2-105 (2006–2011) Investigation of drug-induced weight alterations to identify novel therapeutic strategies for the treatment of obesity, dyslipidemia and diabetes. Principal investigator: Elwin Verheij; partners: Abbott (formerly Solvay Pharmaceuticals), Danone Research (formerly Numico), Leiden University Medical Center, Netherlands Institute for Neurosciences, PRA International, TNO, University Medical Center Groningen http://www.tipharma.com/projects/cardiovascular-diseases/drug-induced-weight-alteration.html
  55. Jackson HC, Cheetham SC, Gregory PC, Antel J (2007). Effect of chronic administration of topiramate and phentermine, alone and in combination, in an animal model of dietary-induced obesity. Neuroscience Program No 629.15, Society for Neuroscience: San Diego, CAGoogle Scholar
  56. Jain KK (2000) An assessment of zonisamide as an anti-epileptic drug. Expert Opin Pharmacother 1:1245–1260PubMedCrossRefGoogle Scholar
  57. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, Saris WH, Van Gaal LF (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance. Lancet 356(9248):2119–2125PubMedCrossRefGoogle Scholar
  58. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL, Investigators SCOUT (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363(10):905–917PubMedCrossRefGoogle Scholar
  59. Johannessen Landmark C (2008) Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 22(1):27–47PubMedCrossRefGoogle Scholar
  60. Jones MW (1998) Topiramate – safety and tolerability. Can J Neurol Sci 25(3):S13–S15PubMedGoogle Scholar
  61. Jones D (2008) End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 7(12):961–962PubMedCrossRefGoogle Scholar
  62. Kelly KM (1998) Gabapentin. Antiepileptic mechanism of action. Neuropsychobiology 38(3):139–144PubMedCrossRefGoogle Scholar
  63. Kennett GA, Clifton PG (2010) New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav 97(1):63–83PubMedCrossRefGoogle Scholar
  64. Kim CS (2003) Zonisamide effective for weight loss in women. J Fam Pract 52:600–601PubMedGoogle Scholar
  65. Kim JH, Yim SJ, Nam JH (2006) A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 82(1):115–117PubMedCrossRefGoogle Scholar
  66. Klein KM, Hamer HM, Reis J, Schmidtke J, Oertel WH, Theisen FM, Hebebrand J, Rosenow F (2005) Weight change in monozygotic twins treated with valproate. Obes Res 13(8):1330–1334PubMedCrossRefGoogle Scholar
  67. Knudsen JF, Thambi LR, Kapcala LP, Racoosin JA (2003) Oligohydrosis and fever in pediatric patients treated with zonisamide. Pediatr Neurol 28(3):184–189PubMedCrossRefGoogle Scholar
  68. Kuo RL, Moran ME, Kim DH, Abrahams HM, White MD, Lingeman JE (2002) Topiramate-induced nephrolithiasis. J Endourol 16:229–231PubMedCrossRefGoogle Scholar
  69. Kushner SF, Khan A, Lane R, Olson WH (2006) Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 8:15–27PubMedCrossRefGoogle Scholar
  70. Kuzmiski JB, Barr W, Zamponi GW, MacVicar BA (2005) Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels. Epilepsia 46(4):481–489PubMedCrossRefGoogle Scholar
  71. Kuzniecky R, Ho S, Pan J, Martin R, Gilliam F, Faught E, Hetherington H (2002) Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 58:368–372PubMedGoogle Scholar
  72. Leniger T, Wiemann M, Bingmann D, Widman G, Hufnagel A, Bonnet U (2002) Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons. Epilepsia 43:469–74PubMedCrossRefGoogle Scholar
  73. Leniger T, Thöne J, Wiemann M (2004) Topiramate modulates pH of hippocampal CA3 neurons by combined effects on carbonic anhydrase and Cl-/HCO3-exchange. Br J Pharmacol 142(5):831–842PubMedCrossRefGoogle Scholar
  74. Leppik IE (2004) Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 13(Suppl 1):S5–S9; discussion S10PubMedCrossRefGoogle Scholar
  75. Levy E, Margolese HC, Chouinard G (2002) Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry 63:1045PubMedCrossRefGoogle Scholar
  76. Lévy E, Agbokou C, Ferreri F, Chouinard G, Margolese HC (2007) Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can J Clin Pharmacol 14(2):e234–e239PubMedGoogle Scholar
  77. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC (2005) Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142:532–546PubMedGoogle Scholar
  78. Liang Y, She P, Wang X, Demarest K (2006) The messenger RNA profiles in liver, hypothalamus, white adipose tissue, and skeletal muscle of female Zucker diabetic fatty rats after topiramate treatment. Metabolism 55:1411–1419PubMedCrossRefGoogle Scholar
  79. Linne Y, Hemmingsson E, Adolfsson B, Ramsten J, Rössner S (2002) Patient expectations of obesity treatment—the experience from a day-care unit. Int J Obes 26:739–741CrossRefGoogle Scholar
  80. Maayan L, Vakhrusheva J, Correll CU (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35:1520–1530PubMedCrossRefGoogle Scholar
  81. Martins PJF, Haas M, Obici S (2010) Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 59(10):2418–2425PubMedCrossRefGoogle Scholar
  82. Maryanoff BE (2009) 2009 Edward E Smissman Award. Pharmaceutical “gold” from neurostabilizing agents: topiramate and successor molecules. J Med Chem 52:3431–3440PubMedCrossRefGoogle Scholar
  83. Maryanoff BE, Nortey SO, Gardocki JF, Shank RP, Dodgson SP (1987) Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-d-fructopyranose sulfamate and related compounds. J Med Chem 30:880–887PubMedCrossRefGoogle Scholar
  84. Maryanoff BE, Costanzo MJ, Nortey SO, Greco MN, Shank RP, Schupsky JJ, Ortegon MP, Vaught JL (1998) Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. J Med Chem 41:1315–1343PubMedCrossRefGoogle Scholar
  85. Masereel B, Rolin S, Abbate F, Scozzafava A, Supuran CT (2002) Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem 45:312–320PubMedCrossRefGoogle Scholar
  86. McAllister EJ, Dhurandhar NV, Keith SW, Aronne LJ, Barger J, Baskin M, Benca RM, Biggio J, Boggiano MM, Eisenmann JC, Elobeid M, Fontaine KR, Gluckman P, Hanlon EC, Katzmarzyk P, Pietrobelli A, Redden DT, Ruden DM, Wang C, Waterland RA, Wright SM, Allison DB (2009) Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr 49(10):868–913PubMedCrossRefGoogle Scholar
  87. McElroy SL, Kotwal R, Hudson JI, Nelson EB, Keck PE (2004) Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry 65:50–56PubMedCrossRefGoogle Scholar
  88. McIntyre RS, Riccardelli R, Binder C, Kusumakar V (2005) Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. Can J Psychiatry 50:415–422PubMedGoogle Scholar
  89. McLean MJ, Bukhari AA, Wamil AW (2000) Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 41(Suppl 1):S21–S24PubMedCrossRefGoogle Scholar
  90. McNaughton NC, Davies CH, Randall A (2004) Inhibition of alpha(1E) Ca(2+) channels by carbonic anhydrase inhibitors. J Pharmacol Sci 95(2):240–247PubMedCrossRefGoogle Scholar
  91. Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H (1990a) Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med J Osaka Univ 39(1–4):13–17PubMedGoogle Scholar
  92. Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H (1990b) [3H]Zonisamide binding in rat brain. Med J Osaka Univ 39(1–4):19–22PubMedGoogle Scholar
  93. Nathan PJ, O'Neill BV, Napolitano A, Bullmore ET (2011) Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs. CNS Neurosci Ther. 17:490–505PubMedCrossRefGoogle Scholar
  94. NCT00203450 (2003) Zonegran for the treatment of weight gain associated with psychotropic medication use: a placebo-controlled trial; Sponsor: Tuscaloosa Research & Education Advancement Corporation; Study Start Date: May 2003Google Scholar
  95. NCT00363376 (2008) A double-blind, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain; Sponsor: Lindner Center of HOPE; Study Start Date: January 2008Google Scholar
  96. NCT00401973 (2006) The assessment of the safety, efficacy, and practicality of an algorithm including amantadine, metformin and zonisamide for the prevention of olanzapine-associated weight gain in outpatients with schizophrenia; Sponsor: Eli Lilly and Company; Study Start Date: November 2006Google Scholar
  97. NCT00734435 (2008) A proof of concept, multi-center, randomized, double-blind, parallel, placebo-controlled, study of zonisamide sustained release (SR) 360 mg versus placebo in the prevention of weight gain associated with olanzapine therapy for psychosis; Sponsor: Orexigen Therapeutics, Inc.; Study Start Date: September 2008Google Scholar
  98. Nickel MK, Nickel C, Muehlbacher M, Leiberich PK, Kaplan P (2005) Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol 25:211–217PubMedCrossRefGoogle Scholar
  99. Ohtahara S (2006) Zonisamide in the management of epilepsy – Japanese experience. Epilepsy Res 68(Suppl 2):S25–S33PubMedCrossRefGoogle Scholar
  100. Oommen KJ, Mathews S (1999) Zonisamide, a new anti-epileptic drug. Clin Neuropharmacol 22:192–200PubMedGoogle Scholar
  101. Perucca E (1997) A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 35:241–256PubMedCrossRefGoogle Scholar
  102. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D (2000) Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res 8:656–663PubMedCrossRefGoogle Scholar
  103. Post RM, Ketter TA, Uhde T, Ballenger JC (2007) Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs 21(1):47–71PubMedCrossRefGoogle Scholar
  104. Raskin P, Donofrio PD, Rosenthal NR, Hewitt DJ, Jordan DM, Xiang J, Vinik AI (2004) Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 63:865–873PubMedGoogle Scholar
  105. Reis J, Tergau F, Hamer HM, Muller HH, Knake S, Fritsch B, Oertel WH, Rosenow F (2002) Topiramate selectively decreases intracortical excitability in human motor cortex. Epilepsia 43:1149–1156PubMedCrossRefGoogle Scholar
  106. Ribacoba Montero R, Salas Puig X (2002) Efficacy and tolerability of long term topiramate in drug resistant epilepsy in adults. Rev Neurol 34:101–105PubMedGoogle Scholar
  107. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y (2000) Influence of topiramate in the regulation of energy balance. Nutrition 16:961–966PubMedCrossRefGoogle Scholar
  108. Richard D, Picard F, Lemieux C, Lalonde J, Samson P, Deshaies Y (2002) The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord 26:344–353PubMedCrossRefGoogle Scholar
  109. Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, Poncelet M, Maruani J, Arnone M, Finance O, Soubrié P, Le Fur G (2004) SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 310:905–914PubMedCrossRefGoogle Scholar
  110. Rogawski MA (2006) Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69(3):273–294PubMedCrossRefGoogle Scholar
  111. Rogawski MA, Löscher W (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5(7):553–564PubMedCrossRefGoogle Scholar
  112. Rosenfeld WE (1997) Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 19:1294–1308PubMedCrossRefGoogle Scholar
  113. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39(1):32–41PubMedCrossRefGoogle Scholar
  114. Russo E, Constanti A, Ferreri G, Citraro R, De Sarro G (2004) Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. Neuropharmacology 46(6):865–878PubMedCrossRefGoogle Scholar
  115. Scheen AJ (2010) Cardiovascular risk-benefit profile of sibutramine. Am J Cardiovasc Drugs 10(5):321–334PubMedCrossRefGoogle Scholar
  116. Schubert S, Brandl U, Brodhun M, Ulrich C, Spaltmann J, Fiedler N, Bauer R (2005) Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets. Brain Res 1058(1–2):129–136PubMedCrossRefGoogle Scholar
  117. Seino M (2004) Review of zonisamide development in Japan. Seizure 13(Suppl 1):S2–S4PubMedCrossRefGoogle Scholar
  118. Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB, Dodgson SJ, Nortey SO, Maryanoff BE (1994) Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 35:450–460PubMedCrossRefGoogle Scholar
  119. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE (2000) An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41(Suppl 1):S3–S9PubMedCrossRefGoogle Scholar
  120. Sills GJ, Leach JP, Kilpatrick WS, Fraser CM, Thompson GG, Brodie MJ (2000) Concentration-effect studies with topiramate on selected enzymes and intermediates of the GABA shunt. Epilepsia 41(Suppl 1):S30–S34PubMedCrossRefGoogle Scholar
  121. Skradski S, White HS (2000) Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 41(Suppl 1):S45–S47PubMedCrossRefGoogle Scholar
  122. Stringer JL (2000) A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat. Epilepsy Res 40:147–153PubMedCrossRefGoogle Scholar
  123. Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7:168–181PubMedCrossRefGoogle Scholar
  124. Supuran CT, Di Fiore A, De Simone G (2008) Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 13(2):383–392PubMedCrossRefGoogle Scholar
  125. Takaya K, Ogawa Y, Isse N, Okazaki T, Satoh N, Masuzaki H, Mori K, Tamura N, Hosoda K, Nakao K (1996) Molecular cloning of rat leptin receptor isoform complementary DNAs – identification of a missense mutation in Zucker fatty (fa/fa) rats. Biochem Biophys Res Commun 225(1):75–83PubMedCrossRefGoogle Scholar
  126. Tanabe M, Sakaue A, Takasu K, Honda M, Ono H (2005) Centrally mediated antihyperalgesic and antiallodynic effects of zonisamide following partial nerve injury in the mouse. Naunyn Schmiedebergs Arch Pharmacol 372:107–114PubMedCrossRefGoogle Scholar
  127. Taverna S, Sancini G, Mantegazza M, Franceschetti S, Avanzini G (1999) Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther 288:960–968PubMedGoogle Scholar
  128. Theisen FM, Cichon S, Linden A, Martin M, Remschmidt H, Hebebrand J (2001) Clozapine and weight gain. Am J Psychiatry 158(5):816PubMedCrossRefGoogle Scholar
  129. Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt H, Hebebrand J, Antel J (2007) No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J 7:275–281PubMedCrossRefGoogle Scholar
  130. Thone J, Leniger T, Splettstosser F, Wiemann M (2008) Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition. Epilepsy Res 79:105–111PubMedCrossRefGoogle Scholar
  131. Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A, Fitchet M (2005) Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 96:243–251PubMedCrossRefGoogle Scholar
  132. Toplak H, Hamann H, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M (2007) Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes 31(1):138–146CrossRefGoogle Scholar
  133. Ueda Y, Doi T, Tokumaru J, Willmore LJ (2003) Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 116(1–2):1–6PubMedCrossRefGoogle Scholar
  134. Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A (2008) Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31(Suppl 2):S229–S240PubMedCrossRefGoogle Scholar
  135. Van Passel L, Arif H, Hirsch LJ (2006) Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Rev Neurother 6:19–31PubMedCrossRefGoogle Scholar
  136. Vasudev K, Macritchie K, Geddes J, Watson S, Young A (2006) Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev CD003384Google Scholar
  137. Vinik A (2005) Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 90:4936–4945PubMedCrossRefGoogle Scholar
  138. Vohora D, Saraogi P, Yazdani MA, Bhowmik M, Khanam R, Pillai KK (2010) Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. Drugs Today (Barc) 46(4):265–277CrossRefGoogle Scholar
  139. Walker RM, DiFonzo CJ, Barsoum NJ, Smith GS, Macallum GE (1988) Chronic toxicity of the anticonvulsant zonisamide in beagle dogs. Fundam Appl Toxicol 11:333–342PubMedCrossRefGoogle Scholar
  140. Wallingford NM, Sinnayah P, Bymaster FP, Gadde KM, Krishnan RK, McKinney AA, Landbloom RP, Tollefson GD, Cowley MA (2008) Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology 33(12):2922–2933PubMedCrossRefGoogle Scholar
  141. Wang PW, Yang YS, Chandler RA, Nowakowska C, Alarcon AM, Culver J, Ketter TA (2008) Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study. J Psychiatr Res 42:451–7PubMedCrossRefGoogle Scholar
  142. Weiergräber M, Henry M, Krieger A, Kamp M, Radhakrishnan K, Hescheler J, Schneider T (2006) Altered seizure susceptibility in mice lacking the Ca(v)2.3 E-type Ca2+ channel. Epilepsia 47(5):839–850PubMedCrossRefGoogle Scholar
  143. Wenzel RG, Schwarz K, Padiyara RS (2006) Topiramate for migraine prevention. Pharmacotherapy 26:375–387PubMedCrossRefGoogle Scholar
  144. Wieczorkiewicz-Plaza A, Plaza P, Maciejewski R, Czuczwar M, Przesmycki K (2004) Effect of topiramate on mechanical allodynia in neuropathic pain model in rats. Pol J Pharmacol 56:275–278PubMedGoogle Scholar
  145. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M (2004) A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 28:1399–1410PubMedCrossRefGoogle Scholar
  146. Wilkes JJ, Nelson E, Osborne M, Demarest KT, Olefsky JM (2005a) Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab 288:E617–E624PubMedCrossRefGoogle Scholar
  147. Wilkes JJ, Nguyen MT, Bandyopadhyay GK, Nelson E, Olefsky JM (2005b) Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in high-fat-fed male Wistar rats. Am J Physiol Endocrinol Metab 289:E1015–E1022PubMedCrossRefGoogle Scholar
  148. Yagi K (2004) Overview of Japanese experience-controlled and uncontrolled trials. Seizure 13(Suppl 1):S11–S15; discussion S16PubMedCrossRefGoogle Scholar
  149. Yamamura S, Hamaguchi T, Ohoyama K, Sugiura Y, Suzuki D, Kanehara S, Nakagawa M, Motomura E, Matsumoto T, Tanii H, Shiroyama T, Okada M (2009) Topiramate and zonisamide prevent paradoxical intoxication induced by carbamazepine and phenytoin. Epilepsy Res 84(2–3):172–186PubMedCrossRefGoogle Scholar
  150. York DA, Singer L, Thomas S, Bray GA (2000) Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 16(10):967–975PubMedCrossRefGoogle Scholar
  151. Zullino DF, Krenz S, Besson J (2003) AMPA blockade may be the mechanism underlying the efficacy of topiramate in PTSD. J Clin Psychiatry 64:219–220PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Pharmaceutical InstituteUniversity of BonnBad MünderGermany
  2. 2.Department of Child and Adolescent Psychiatry, LVR-Klinikum EssenKliniken/Institut der Universität Duisburg-EssenEssenGermany

Personalised recommendations